Provectus Pharmaceuticals (PVCT) Stock Statistics & Valuation Metrics

Provectus Pharmaceuticals has a market cap or net worth of $21.01M. The enterprise value is $24.41M.

Provectus Pharmaceuticals has 420,279,880 shares outstanding. The number of shares has decreased by -2.65% in one year.

Provectus Pharmaceuticals’s return on equity (ROE) is 0.86 and return on invested capital (ROIC) is 145.74%.

The current PE Ratio of Provectus Pharmaceuticals is ―. Provectus Pharmaceuticals’s PEG ratio is -0.31.

In the last 12 months, Provectus Pharmaceuticals had revenue of 336.11K and earned -5.43M in profits. Earnings per share was -0.01.

In the last 12 months, operating cash flow was -3.33M and capital expenditures 0.00, giving a free cash flow of -3.33M billion.

Provectus Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Provectus Pharmaceuticals upcoming earnings date is ―, ―.

Provectus Pharmaceuticals as a current ratio of 0.08, with Debt / Equity ratio of -47.26%

In the past 12 months, Provectus Pharmaceuticals has paid 0.00 in taxes.

Provectus Pharmaceuticals EV to EBITDA ratio is -5.41, with an EV/FCF ratio of -7.88.

Provectus Pharmaceuticals has $251.29K in cash and marketable securities with $2.98M in debt, giving a net cash position of -$2.73M billion.

Gross margin is -13.67%, with operating margin of -1441.28%, and net profit margin of -1615.81%.

The average price target for Provectus Pharmaceuticals is ―, which is 11.43% higher than the current price. The consensus rating is ―